|
LY353381 in Preventing Breast Cancer in Women With Hyperplasia Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about LY353381 in Preventing Breast Cancer in Women With Hyperplasia conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. LY353381 in Preventing Breast Cancer in Women With Hyperplasia Clinical research trials and LY353381 in Preventing Breast Cancer in Women With Hyperplasia health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like LY353381 in Preventing Breast Cancer in Women With Hyperplasia. LY353381 in Preventing Breast Cancer in Women With Hyperplasia Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a LY353381 in Preventing Breast Cancer in Women With Hyperplasia clinical trial. Human subjects often get the best healthcare available for their LY353381 in Preventing Breast Cancer in Women With Hyperplasia condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > LY353381 in Preventing Breast Cancer in Women With Hyperplasia  LY353381 in Preventing Breast Cancer in Women With Hyperplasia
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
For Condition: Breast Cancer
Status: No longer recruiting
Sponsor(s): University of Kansas , National Cancer Institute (NCI)
Synopsis: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of LY353381 may be an effective way to prevent the development of breast cancer in women who have hyperplasia. PURPOSE: Randomized phase II trial to study the effectiveness of LY353381 in preventing breast cancer in women who have hyperplasia.
Details: OBJECTIVES: - Determine if LY353381 hydrochloride improves baseline cytology in women at high risk for breast cancer. - Determine if this drug modulates other potential surrogate endpoint biomarkers or drug effect biomarkers. - Determine if cytologic improvement is associated with initial presentation of the various stratification factors. - Determine whether cytology is correlated with other potential surrogate endpoint biomarkers or drug effect biomarkers and whether change in cytology is correlated with change in the other biomarkers. - Monitor the effects of this drug in terms of quality of life and women's health. OUTLINE: This is a randomized, double-blind, multicenter study followed by an open-label study for both arms. Patients are stratified according to cytologic status (hyperplasia with atypia vs hyperplasia without atypia), mutation status (known carrier for BRCA1 or BRCA2 genes vs known not to be a carrier of mutant genes), menopausal status (premenopausal vs postmenopausal), estrogen-receptor status, and participating center. Patients are randomized to one of two treatment arms. - Arm I: Patients receive oral LY353381 hydrochloride once daily for 6 months. - Arm II: Patients receive oral placebo once daily for 6 months. Patients in both arms then receive oral LY353381 hydrochloride for an additional 6 months. Quality of life is assessed at baseline and then at 6 and 12 months. Patients are followed at 2 weeks and then annually for 5 years. PROJECTED ACCRUAL: A total of 210-220 patients will be accrued for this study within 2.5-3 years.
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Current random fine needle breast aspiration (FNA) evidence of 1 of the following: - Hyperplasia with atypia - Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4% - Hyperplasia without atypia but with a BRCAPRO risk of at least 25% - Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2 - Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer - FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women - Classified as ACR class I-III on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries, must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausal - No ovarian cysts felt to be possibly or probably non-physiologic that have not resolved to gynecologist's satisfaction on repeat sonogram - Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2 - No active cancer (e.g., detectable disease) - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 and over Sex: - Female Menopausal status: - Any Performance status: - Not specified Life expectancy: - At least 12 months Hematopoietic: - Hemoglobin greater than 10 g/dL - Granulocyte count greater than 1,000/mm^3 - No deficiencies in protein C, protein S, or antithrombin III - No activated protein C resistance Hepatic: - Albumin greater than 3.0 g/dL - Bilirubin less than 1.5 mg/dL - AST less than 100 U/L - Alkaline phosphatase less than 200 U/L Renal: - Creatinine less than 1.5 mg/dL Cardiovascular: - No history of deep venous thrombosis not related to trauma or pregnancy - No severe coronary artery disease - No history of prior stroke Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 3 months after study - No other active cancer - No retinal vein thrombosis - No concurrent severe poorly controlled migraine - No factor V Leiden mutation carrier PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 12 months since prior immunotherapy Chemotherapy: - At least 3 months between completion of prior KUMC phase II difluoromethylornithine (DFMO) study and baseline aspiration - At least 12 months since prior chemotherapy Endocrine therapy: - Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration - Must continue all hormone replacement therapy and/or oral contraceptives that were being taken at time of baseline aspiration - At least 12 months since prior tamoxifen, raloxifene, or other antihormonal therapy Radiotherapy: - At least 3 months since prior radiotherapy Surgery: - At least 6 months between prior oophorectomy and baseline aspiration Other: - At least 2 weeks since the start of other new medication that would be ingested for 1 or more months
Total Enrollment:
Location and Contact Information:
Overall Study Official:
CarolFabian, Study Chair, University of Kansas
U.S. Oncology Research, Inc.
Dallas, Texas, 75246
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160-7820
United States
Additional Information:
Study ID Numbers: CDR0000067918; KUMC-HSC-7264-97,NCI-P00-0146
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005879
Other Breast Cancer Studies:
1. Vinorelbine and XR9576 to Treat Cancer
2. Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
3. Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin
4. Flavopiridol in Treating Patients With Metastatic or Unresectable Mantle Cell Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, or Invasive Breast Cancer
5. Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Related Studies:
Other Breast Cancer Clinical Trials
Other Kansas Clinical Trials
Other Kansas City Clinical Trials
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
|
|
|
|
|
|
|
|
